We thus decided to investigate B efficacy, the distribution of a series of parameters involved in angiogenesis and inflammatory processes, and RAS and BRAF mutations in relation to tumor localization in a case series of metastatic colorectal cancer patients enrolled in the phase III multicenter, prospective, randomized “Italian Trial in Advanced Colorectal Cancer (ITACa)” trial [21] The ITACa trial is registered on ClinicalTrials.gov (NCT01878422). This evidence concerns the gene BRAF and colorectal cancer.